Journal of pain and symptom management
-
J Pain Symptom Manage · Sep 2019
ReviewStrategies for pain assessment in adult patients with delirium: a scoping review.
Pain and delirium are highly prevalent in the same patient groups. Disturbances in attention, awareness, and cognition are characteristics for delirium and can compromise pain assessment. ⋯ The current literature is insufficient to guide clinical practice in pain assessment in patients with delirium. Future research will be needed to address the validity of existing pain assessment instruments, apply theoretical and conceptual understandings of pain and delirium, and build on prior studies to close evidence gaps.
-
J Pain Symptom Manage · Sep 2019
Randomized Controlled TrialTo what extent do the NRS and CRQ capture change in patients' experience of breathlessness in advanced disease? Findings from a mixed-methods double blind randomised feasibility trial.
Chronic or refractory breathlessness is common and distressing. To evaluate new treatments, outcome measures that capture change in patients' experience are needed. ⋯ This study found that the NRS using the question "How bad has your breathlessness felt at its worst over the past 24 hours?" captured change across multiple domains, and therefore may be an appropriate primary outcome measure in trials in this population. Future work should confirm the construct validity of this question.
-
J Pain Symptom Manage · Sep 2019
Clinical TrialCebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks.
Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. For cancer patients, frequently experiencing multimorbidities and often exposed to polypharmacy, cebranopadol is easy to handle given its once-daily dosing, the small tablet size that enables swallowing, and the option to flexibly titrate to an effective dose. ⋯ Our data suggest that cebranopadol was safe and well tolerated when administered for up to 26 weeks in patients with chronic cancer-related pain who were previously treated with cebranopadol or morphine prolonged release.